Alnylam Pharmaceuticals, Inc.
ALNYNASDAQHealthcare● Active
$290.29
$-12.77(-4.21%)
Market Cap$38.8B
P/E Ratio—
52W High$495.55
52W Low$283.1
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALNY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$1.51
Est. $0.87 · +73.2%
Revenue
$1.17B
Est. $1.12B · +4.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
ALNY reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $1.63 | — | — | — | $1.32B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $0.87 | $1.51 | +73.2% | $1.17B | $1.12B | +4.6% |
| ▼ Q1 FY2026 | Feb 12, 2026 | $1.16 | $0.82 | -29.3% | $1.10B | $1.15B | -4.5% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.56 | $2.90 | +416.9% | $1.25B | $0.96B | +30.2% |
| ▲ Q3 FY2025 | Jul 31, 2025 | -$0.54 | $0.32 | +158.8% | $0.77B | $0.66B | +16.7% |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.89 | -$0.01 | +98.9% | $0.59B | $0.59B | +1.6% |
| ▲ Q1 FY2025 | Feb 13, 2025 | -$0.62 | $0.06 | +109.7% | $0.59B | $0.58B | +1.8% |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$0.92 | -$0.50 | +45.5% | $0.50B | $0.53B | -6.0% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$1.63
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$1.51
EPS Est.
$0.87
EPS Surpr.
+73.2%
Revenue
$1.17B
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
$0.82
EPS Est.
$1.16
EPS Surpr.
-29.3%
Revenue
$1.10B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$2.90
EPS Est.
$0.56
EPS Surpr.
+416.9%
Revenue
$1.25B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$0.32
EPS Est.
-$0.54
EPS Surpr.
+158.8%
Revenue
$0.77B
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.89
EPS Surpr.
+98.9%
Revenue
$0.59B
Q1 FY2025
Feb 13, 2025Beat
EPS Actual
$0.06
EPS Est.
-$0.62
EPS Surpr.
+109.7%
Revenue
$0.59B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$0.50
EPS Est.
-$0.92
EPS Surpr.
+45.5%
Revenue
$0.50B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $3.36 | $3.70 | $4.20 | 5 |
| Q3 FY2028 | $3.56 | $3.92 | $4.45 | 5 |
| Q2 FY2028 | $3.61 | $3.97 | $4.51 | 5 |
| Q1 FY2028 | $3.70 | $4.08 | $4.63 | 5 |
| Q4 FY2027 | $2.83 | $3.12 | $3.54 | 4 |
| Q3 FY2027 | $2.35 | $2.59 | $2.94 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $2.1B | $2.3B | $2.5B | 6 |
| Q3 FY2028 | $2.1B | $2.3B | $2.5B | 6 |
| Q2 FY2028 | $2.1B | $2.3B | $2.5B | 6 |
| Q1 FY2028 | $2.1B | $2.2B | $2.5B | 6 |
| Q4 FY2027 | $2.0B | $2.1B | $2.3B | 7 |
| Q3 FY2027 | $1.8B | $2.0B | $2.2B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +73.2% | $301.19 | $309.49 | +2.76% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -29.3% | $322.28 | $308.48 | -4.28% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +416.9% | $481.59 | $449.56 | -6.65% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +158.8% | $339.80 | $392.24 | +15.43% |
| ▲ Q2 FY2025 | May 1, 2025 | +98.9% | $263.24 | $255.13 | -3.08% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +109.7% | $265.96 | $264.89 | -0.40% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +45.5% | $281.49 | $266.59 | -5.29% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +152.3% | $237.46 | $268.61 | +13.12% |
Q2 FY2026+2.76%
Report Date
Apr 30, 2026
EPS Beat/Miss
+73.2%
Price Before
$301.19
Price After
$309.49
Q1 FY2026-4.28%
Report Date
Feb 12, 2026
EPS Beat/Miss
-29.3%
Price Before
$322.28
Price After
$308.48
Q4 FY2025-6.65%
Report Date
Oct 30, 2025
EPS Beat/Miss
+416.9%
Price Before
$481.59
Price After
$449.56
Q3 FY2025+15.43%
Report Date
Jul 31, 2025
EPS Beat/Miss
+158.8%
Price Before
$339.80
Price After
$392.24
Q2 FY2025-3.08%
Report Date
May 1, 2025
EPS Beat/Miss
+98.9%
Price Before
$263.24
Price After
$255.13
Q1 FY2025-0.40%
Report Date
Feb 13, 2025
EPS Beat/Miss
+109.7%
Price Before
$265.96
Price After
$264.89
Q4 FY2024-5.29%
Report Date
Oct 31, 2024
EPS Beat/Miss
+45.5%
Price Before
$281.49
Price After
$266.59
Q3 FY2024+13.12%
Report Date
Aug 1, 2024
EPS Beat/Miss
+152.3%
Price Before
$237.46
Price After
$268.61
Avg Beat Reaction+2.27%
Avg Miss Reaction-4.28%
Beat Rate7 / 8 quarters
Largest Move+15.43% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALNY ends December
Alnylam Pharmaceuticals, Inc. (ALNY) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $1.51 — beating the analyst consensus of $0.87 by +73.2%. The next ALNY earnings date is expected around September 1, 2026.
Each quarter, investors track ALNY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALNY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALNY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALNY earnings · 5 questionsAlnylam Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ALNY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALNY historically reports after market close (AMC).
ALNY earnings datewhen is ALNY earningsALNY next earnings datewhen does ALNY report earningsALNY earnings calendar
▸ Source: FMP · Alnylam Pharmaceuticals, Inc. SEC filings · US GAAP · Alnylam Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026